Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
40
BIO Quote, Financials, Valuation and Earnings
Last price:
$249.55
Seasonality move
:
-0.22%
Day range:
$244.45 - $249.38
52-week range:
$211.43 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.73x
P/B ratio:
1.01x
Volume:
208K
Avg. volume:
358.2K
1-year change:
-21.39%
Market cap:
$6.7B
Revenue:
$2.6B
EPS (TTM):
-$76.20
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $315.33, Bio-Rad Laboratories has an estimated upside of 27.53% from its current price of $247.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $245.00 representing 100% downside risk from its current price of $247.26.
Fair Value
-
According to the consensus of 4 analysts, Bio-Rad Laboratories has 27.53% upside to fair value with a price target of $315.33 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories has underperformed the S&P 500 by -2.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $585.4M.
Earnings Growth
-
Bio-Rad Laboratories earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported earnings per share of $2.29.
Enterprise value:
6.3B
EV / Invested capital:
--
Price / LTM sales:
2.73x
EV / EBIT:
--
EV / Revenue:
2.47x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
18.88x
Price / Operating cash flow:
20.91x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-20.89%
Net Income Margin (TTM):
-85.17%
Return On Equity:
-29.59%
Return On Invested Capital:
-25.43%
Operating Margin:
4.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.6B | $2.5B | $610.8M | $585.4M | |
| Gross Profit | $1.5B | $1.4B | $1.4B | $325.9M | $306M | |
| Operating Income | $390.6M | $320.5M | $248M | $44.6M | $23.7M | |
| EBITDA | -$65.5M | -$247.1M | -$2.5B | $540.5M | $133.5M | |
| Diluted EPS | -$6.43 | -$10.36 | -$76.20 | $13.45 | $2.29 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $3.3B | $3.3B | $3.1B | $3B | |
| Total Assets | $13.9B | $14.4B | $13.7B | $12.6B | $9.5B | |
| Current Liabilities | $609.9M | $648.3M | $589.6M | $466.2M | $506.6M | |
| Total Liabilities | $3.3B | $4.2B | $3.9B | $3.6B | $2.8B | |
| Total Equity | $10.6B | $10.2B | $9.8B | $9.1B | $6.7B | |
| Total Debt | $1.2M | $1.2B | $1.2B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $242M | $346.6M | $515.3M | $69.8M | $129.9M | |
| Cash From Investing | -$361.9M | $47.6M | -$114.2M | -$43.1M | $2.9M | |
| Cash From Financing | -$212.4M | -$429.9M | -$316.5M | -- | -$97.7M | |
| Free Cash Flow | $125.1M | $185.4M | $332.1M | $29.6M | $95.5M | |
BIO
Sector
Market Cap
$6.7B
$34.4M
Price % of 52-Week High
63.73%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
4.46%
-1.01%
1-Year Price Total Return
-21.39%
-37.36%
Beta (5-Year)
0.946
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$251.64
200-day SMA
Sell
Level
$290.96
Bollinger Bands (100)
Buy
Level
230.39 - 256.93
Chaikin Money Flow
Buy
Level
36.4M
20-day SMA
Buy
Level
$245.29
Relative Strength Index (RSI14)
Buy
Level
53.63
ADX Line
Buy
Level
16.55
Williams %R
Neutral
Level
-63.909
50-day SMA
Buy
Level
$237.85
MACD (12, 26)
Buy
Level
4.61
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
29.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8785)
Sell
CA Score
(Annual)
Level (-0.378)
Buy
Beneish M-Score
(Annual)
Level (-3.6873)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.345)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $315.33.
-
Where Will Bio-Rad Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $315.33 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories?
Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $245.00.
-
What Is Bio-Rad Laboratories's Price Target?
The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $315.33 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.
-
What Is The Bio-Rad Laboratories Share Price Today?
Bio-Rad Laboratories was last trading at $249.55 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $247.26 per share.
-
How To Buy Bio-Rad Laboratories Stock Online?
In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
